Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
NCT01358331 · Merck Sharp & Dohme LLC · PHASE1 · terminated · last registry update 2020-04-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAPK3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-05-01Results posted on the registry: Washington University School of Medicine, BVD-523 + Nab-paclitaxel (NCT02608229)
- 2020-03-20Results posted on the registry: BioMed Valley Discoveries, Inc, BVD-523 (NCT01781429)
- 2019-06-17Results posted on the registry: BioMed Valley Discoveries, Inc, [14C]-BVD-523 (NCT02994732)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision